Pair page — what's published on the two together
Cagrilintide with Tirzepatide
Studied together once, in rats: a comparison group in a 2026 study built around cagrilintide with retatrutide. No study in people.
- Studied together
- 1 rat study, as a comparison group (2026)
- Cagrilintide
- Gray market · evidence: Controlled trials
- Tirzepatide
- FDA approved · evidence: Approved drug
Studied Together
Obese male rats, a comparison group (Petersen et al., 2026)
- What was given — Male rats made obese on a high-fat, high-sucrose diet were dosed daily for 14 days with vehicle or one of three cagrilintide pairs at 5 + 5 nmol/kg: with tirzepatide, with semaglutide or with retatrutide; 10 rats per group. No group in this experiment got cagrilintide or tirzepatide alone (the paper’s figures and published source data).
- What it found — Weight changed −10.6% on cagrilintide with tirzepatide, −13.1% with semaglutide and −17.6% with retatrutide, against +1.9% on vehicle (each pair vs vehicle, P < 0.0001). The tirzepatide pair lost less than the semaglutide pair (P = 0.0210) and the retatrutide pair (P < 0.0001). All three pairs cut food intake against vehicle (P < 0.0001).
- Limits — One lab’s two-week study in male rats at one dose; without single-drug groups it cannot show whether the pair does more than either drug. Not blinded. Funding included Novo Nordisk Foundation grants; three authors co-founded a company developing obesity drugs, and some report speaking or counselling fees or research support from Novo Nordisk, Eli Lilly or Zealand Pharma.
No study in people has tested cagrilintide with tirzepatide. The three registered trials that name both compare CagriSema with tirzepatide; no one in them takes the two together (ClinicalTrials.gov, searched October 3, 2026).
Each Compound's Evidence
What each has shown on its own, from its Kalios card. The full profiles carry the sources.
Evidence: Controlled trials. The other half of Novo's CagriSema combo. Alone it's gray-market; paired, 20.4% weight loss at 68 weeks.
Evidence: Approved drug. Zepbound: the weekly shot that beat semaglutide head-to-head. Main trial: 20.9% weight loss at 72 weeks.
Legal Status
Cagrilintide: Gray market. No FDA ruling — not on any list.
Tirzepatide: FDA approved. Prescribed by a doctor, made by a manufacturer.
References
- Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026. PMID: 42744908.
Last updated: October 3, 2026 | A literature lookup, not a recommendation to combine anything.